Publications by authors named "T Guimard"
Infectious aneurysms represent <5 % of cases [1] with a crucial and challenging diagnosis. Staphylococcus, Streptococcus, Enterobacteria are mostly involved but unusual pathogens like Listeria monocytogenes can be responsible. Collecting data of these rare situations allows to improve diagnosis.
View Article and Find Full Text PDFArticle Synopsis
- The study examined a cluster of acute epiglottitis cases in Vendée, France, from October to December 2022, finding it to be an unusual occurrence.
- Six male patients, averaging 42 years old, were hospitalized, with risk factors like smoking and alcohol use prevalent among them; one patient died.
- A significant rise in acute epiglottitis cases was confirmed through various data sources, which coincided with a national increase in the circulation of streptococcus A.
Efficacy of oral 20-hydroxyecdysone (BIO101), a MAS receptor activator, in adults with severe COVID-19 (COVA): a randomized, placebo-controlled, phase 2/3 trial.
Suzana Margareth Lobo Gaétan Plantefève Girish Nair Adilson Joaquim Cavalcante Nara Franzin de Moraes Thomas Guimard
EClinicalMedicine
February 2024
Article Synopsis
- The study examined whether Mas-receptor activation by BIO101 could help balance the Renin-Angiotensin System and reduce severe respiratory issues in hospitalized COVID-19 patients.
- It was a double-blind, randomized trial involving 238 participants, with findings showing a 11.4% lower rate of respiratory failure or early death in the BIO101 group compared to placebo.
- Results suggest BIO101 may reduce the risk of severe outcomes in COVID-19 patients, although further research is needed due to the low sample size.
Background: Surgical site infections (SSIs), mainly caused by Staphylococcus aureus, pose a significant economic burden in Europe, leading to increased hospitalization duration, mortality, and treatment costs, particularly with drug-resistant strains such as meticillin-resistant S. aureus.
Aim: To conduct a case-control study on the economic impact of S.
Efficacy and safety of an early oral switch in low-risk Staphylococcus aureus bloodstream infection (SABATO): an international, open-label, parallel-group, randomised, controlled, non-inferiority trial.
Achim J Kaasch Luis Eduardo López-Cortés Jesús Rodríguez-Baño José Miguel Cisneros M Dolores Navarro Thomas Guimard
Lancet Infect Dis
May 2024
Article Synopsis
- This study investigates the effectiveness and safety of switching from intravenous to oral antibiotics after 5-7 days in patients with low-risk Staphylococcus aureus bloodstream infections.
- Conducted across 31 hospitals in Europe, the trial aimed to determine if early oral therapy could maintain patient safety and reduce complications compared to ongoing intravenous treatment.
- Due to slow participant recruitment, the trial was halted early with 215 participants, and the analysis was adjusted to ensure statistical validity, focusing on whether oral treatment led to acceptable complication rates compared with the traditional intravenous approach.